MIT study links APOE4 to myelin changes in Alzheimer’s risk
BROBROK News · Based on reporting by DiarioBitcoin ·
A MIT study connected APOE4, a major late-onset Alzheimer’s risk factor, with reduced Wnt signaling in oligodendrocytes and lipid buildup in lab models. The team tested an experimental intervention that improved myelination in cells, organoids and mice, but the findings remain preclinical.
Key points
- APOE4 was linked to lower Wnt pathway activity in oligodendrocytes.
- The change was associated with lipid droplet buildup and weaker myelination.
- In lab models, inhibiting GSK3b reduced lipids and improved myelination.
- The results came from cells, organoids and mice.
- The authors say the work is not proof of a human therapy.
Why it matters
The study points to a cellular pathway that may help explain how APOE4 raises Alzheimer’s risk. It also offers a research direction, but the findings are still too early for clinical use.
Original headline: “APOE4 debilita la mielina y abre una nueva pista sobre el riesgo de Alzheimer”
Read the original on DiarioBitcoin
Summary and analysis written by BROBROK News from the original report. Read the full story on the source website. Not investment advice.